UBS Group reiterated their buy rating on shares of GlaxoSmithKline (NYSE:GSK) in a research note published on Monday morning, www.boersen-zeitung.de reports.

Several other brokerages have also commented on GSK. Zacks Investment Research upgraded shares of GlaxoSmithKline from a hold rating to a buy rating and set a $46.00 price target on the stock in a research note on Wednesday, October 18th. JPMorgan Chase & Co. restated a neutral rating on shares of GlaxoSmithKline in a research note on Wednesday, October 18th. Bank of America lowered shares of GlaxoSmithKline from a buy rating to a neutral rating in a research note on Thursday, October 26th. TheStreet upgraded shares of GlaxoSmithKline from a c+ rating to a b rating in a research note on Wednesday, October 25th. Finally, Investec lowered shares of GlaxoSmithKline from a buy rating to a hold rating in a research note on Monday, November 6th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $38.57.

GlaxoSmithKline (NYSE GSK) traded up $0.02 during trading on Monday, reaching $38.17. 4,316,100 shares of the company’s stock traded hands, compared to its average volume of 6,061,258. The firm has a market cap of $92,950.00, a price-to-earnings ratio of 28.92, a PEG ratio of 2.36 and a beta of 0.97. The company has a current ratio of 0.64, a quick ratio of 0.44 and a debt-to-equity ratio of 2.96. GlaxoSmithKline has a 1 year low of $34.52 and a 1 year high of $44.53.

GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.85 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.84 by $0.01. GlaxoSmithKline had a net margin of 7.79% and a return on equity of 115.30%. research analysts expect that GlaxoSmithKline will post 2.92 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 11th. Investors of record on Friday, November 10th were issued a dividend of $0.5037 per share. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.49. This represents a $2.01 annualized dividend and a dividend yield of 5.28%. The ex-dividend date of this dividend was Thursday, November 9th. GlaxoSmithKline’s dividend payout ratio is currently 154.55%.

In other news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The stock was acquired at an average cost of $14.00 per share, with a total value of $5,999,994.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 10.00% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Principal Financial Group Inc. bought a new stake in GlaxoSmithKline in the 2nd quarter valued at $602,000. King Luther Capital Management Corp boosted its holdings in GlaxoSmithKline by 1.0% in the 2nd quarter. King Luther Capital Management Corp now owns 5,432 shares of the pharmaceutical company’s stock valued at $234,000 after purchasing an additional 55 shares during the period. Bahl & Gaynor Inc. boosted its holdings in GlaxoSmithKline by 0.9% in the 2nd quarter. Bahl & Gaynor Inc. now owns 17,481 shares of the pharmaceutical company’s stock valued at $673,000 after purchasing an additional 150 shares during the period. Stevens Capital Management LP boosted its holdings in GlaxoSmithKline by 17.1% in the 2nd quarter. Stevens Capital Management LP now owns 40,674 shares of the pharmaceutical company’s stock valued at $1,754,000 after purchasing an additional 5,933 shares during the period. Finally, PNC Financial Services Group Inc. boosted its holdings in GlaxoSmithKline by 0.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 1,133,608 shares of the pharmaceutical company’s stock valued at $48,881,000 after purchasing an additional 3,698 shares during the period. 9.80% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “GlaxoSmithKline (GSK) Rating Reiterated by UBS Group” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/glaxosmithkline-gsk-rating-reiterated-by-ubs-group/1814033.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.